RDS Inhibitors
RDS Inhibitors are a set of chemical compounds that can decrease the functional activity of RDS through specific signaling pathways or biological processes that it is directly involved in. Mucolytic agents like Acetylcysteine and mucoactive drugs like Ambroxol could inhibit the functional activity of RDS by disrupting the mucus layer where surfactant proteins function or by altering the mucus environment, respectively, causing a decrease in their activity.
Phosphodiesterase inhibitors like Sildenafil can inhibit the degradation of cGMP, leading to smooth muscle relaxation and vasodilation. This could decrease the surfactant proteins' activity by altering the lung's vascular tone and perfusion, indirectly affecting RDS. Non-selective beta blockers like Propranolol and calcium channel blockers like Verapamil could affect the functional activity of surfactant proteins in RDS by altering the perfusion and oxygenation of the lungs. Glucocorticoids like Dexamethasone can influence lung maturation and surfactant production, leading to a decrease in the activity of surfactant proteins involved in RDS with excessive or prolonged use. NSAIDs like Indomethacin and loop diuretics like Furosemide can influence inflammation and fluid exchange in the lungs or fluidbalance, affecting the functional activity of surfactant proteins by altering the alveolar environment in RDS.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $34.00 $74.00 $270.00 $114.00 | 34 | |
Acetylcysteine is a mucolytic agent that reduces the viscosity of mucus. In the context of RDS, it can potentially inhibit the functional activity of surfactant proteins by disrupting the mucus layer where these proteins function, causing a decrease in their activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta blocker that can reduce cardiac output and influence perfusion. This could potentially affect the functional activity of surfactant proteins in RDS by altering the perfusion and oxygenation. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker that can affect smooth muscle contraction and vasodilation. This could potentially affect the functional activity of surfactant proteins in RDS by altering lung perfusion and oxygenation. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone is a glucocorticoid that can influence lung maturation and surfactant production. Although it is typically used to promote surfactant production, an excessive or prolonged use could potentially lead to a decrease in the activity of surfactant proteins involved in RDS. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin is an agent that can influence inflammation and fluid exchange in the lungs. This could potentially affect the functional activity of surfactant proteins by altering the alveolar environment in RDS. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide is a loop diuretic that can influence fluid balance and potentially affect hydration status. This could potentially affect the functional activity of surfactant proteins by altering the alveolar environment in RDS. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine is a central nervous system stimulant that can influence respiratory drive and lung function. This could potentially affect the functional activity of surfactant proteins by altering lung function and oxygenation in RDS. | ||||||